Cue Biopharma (CUE) Cash from Financing Activities (2017 - 2025)

Cue Biopharma has disclosed Cash from Financing Activities across 9 years of filings, most recently posting $9.5 million for Q4 2025.

• Cash from Financing Activities for Q4 2025 came in at $9.5 million, up 1118.45% year-over-year; the trailing twelve-month figure through Dec 2025 was $26.3 million (up 156.67% YoY), and the FY2025 annual result was $26.3 million, up 156.67% from the prior year.
• Cash from Financing Activities came in at $9.5 million for Q4 2025 at Cue Biopharma, up from $1000.0 in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $27.4 million in Q4 2022 to a low of -$1.0 million in Q2 2024.
• The 5-year median for Cash from Financing Activities is $3.5 million (2023), against an average of $6.1 million.
• Across the five-year window, Cash from Financing Activities soared 51088.89% in 2023 and plunged 147.6% in 2024, its largest moves.
• Cue Biopharma's Cash from Financing Activities stood at $7.4 million in 2021, then jumped by 271.2% to $27.4 million in 2022, then tumbled by 82.55% to $4.8 million in 2023, then plunged by 119.49% to -$932000.0 in 2024, then jumped by 1118.45% to $9.5 million in 2025.
• The last three Cash from Financing Activities figures came in at $9.5 million (Q4 2025), $1000.0 (Q3 2025), and $17.8 million (Q2 2025), per Business Quant data.